EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Feasibility of an Integrated Digital and Pharmacological Approach Targeting Blood Lipids in Atherosclerotic Cardiovascular Disease Management

Xu Yi, Qiu Weiyu, Li Yan, Lan Xianwu, Wu Shaorong

Cardiovascular Innovations and Applications · 2024 · 9 (1)

DOI: 10.15212/cvia.2024.0002 ↗
AbstractBibliografische Angaben

Abstract

Objectives: Strong evidence supports the importance of lipid-lowering and exercise therapies in the long-term therapy of atherosclerotic cardiovascular disease (ASCVD). Establishing efficient comprehensive intervention programs that combine pharmacological and exercise prescription is crucial to investigate with the aid of digital technologies. Methods: A convenience sample of 25 ASCVD patients (57.8 ± 9.5 years, 76% males) was gathered. All participants were prescribed with 12-week home exercise program supervised by an app and bimonthly 75mg alirocumab subcutaneous injections. Follow up visits were scheduled at the end of 4th and 12th week. Results: Nineteen participants completed the program with a retention rate of 76%. Sixteen (84.2%) participants received all six doses of alirocumab. The total management time of the 12-week program added up to 65.47 minutes per patient. Satisfaction score was 4.2 ± 0.6 and the User Version of the Mobile Application Rating Scale (uMARS) overall objective quality score on the app was 3.4 ± 0.7. At the 4-week and 12-week follow-ups, LDL-C levels reduced compared to baseline (−1.5 ± 0.8 mmol/L, P < 0.001, −1.6 ± 0.8 mmol/L, P < 0.001, respectively), along with TC (−1.8 ± 1.2 mmol/L, P < 0.001, −1.6 ± 1.3 mmol/L, P < 0.001, respectively), but not TG, HDL-C, GAD-7 and PHQ-9. Conclusion: The integrated pharmaceutical and digital ERx intervention program was feasible and well accepted in ASCVD patients.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →